ADI invites Biogen to present aducanumab data
This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.
News & events
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
Featured news and events
World Alzheimer Report 2020: Design, Dignity, Dementia: dementia-related design and the built environment
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
Italian national dementia plan to receive funding for first time
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI’s 34th international and 1st virtual conference opens
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
People with dementia must be priority for COVID-19 vaccine access
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Open to all: British Land and Canada Water
Emma Cariaga and Ginny Warr of British Land explore what inclusive design means for older people and for business growth. They look at Canada Water, where British Land is creating London’s first new town centre in over 100 years, and at activities across the company’s wider portfolio.
‘Dementia, lessons learned from Qatar’ launched at WISH 2020 Qatar Summit
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
New Alzheimer’s disease data platform launched
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Souvenaid results offer hope for those with early Alzheimer’s disease, including Mild Cognitive Impairment
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
Evidence considered at FDA Advisory Committee for potential first new Alzheimer’s disease treatment in decades
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.